Equity - Additional Information (Details) $ / shares in Units, $ in Thousands |
|
|
|
|
|
|
|
|
3 Months Ended |
12 Months Ended |
|
|
Oct. 15, 2021
shares
|
Jul. 27, 2021
USD ($)
shares
|
May 24, 2021
shares
|
May 23, 2021 |
Mar. 28, 2021
USD ($)
$ / shares
shares
|
Oct. 23, 2020
USD ($)
$ / shares
shares
|
Jul. 15, 2020
USD ($)
$ / shares
shares
|
Jul. 06, 2020
USD ($)
$ / shares
shares
|
Sep. 30, 2021
shares
|
Dec. 31, 2021
USD ($)
D
$ / shares
shares
|
Dec. 31, 2020
USD ($)
$ / shares
shares
|
Jul. 23, 2021
shares
|
Mar. 31, 2020
shares
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock, shares authorized |
|
|
|
|
|
|
|
|
|
500,000,000
|
500,000,000
|
|
|
Common stock, par value | $ / shares |
|
|
|
|
|
|
|
|
|
$ 0.001
|
$ 0.001
|
|
|
Issuance of common stock for exercise of warrants and Unit Purchase Options (in shares) |
|
|
|
|
|
|
|
|
|
3,830,586
|
|
|
|
Number of shares issued upon exercise of warrants |
|
1,833,596
|
|
|
|
|
|
|
|
516,025
|
|
|
|
Issuance of common stock for exercise of warrants and Unit Purchase Options | $ |
|
|
|
|
|
|
|
|
|
$ 16,699
|
|
|
|
Contingently issuable Earnout Shares Excluded from EPS computation |
|
|
|
|
|
|
|
|
185,472
|
|
|
|
|
Common stock issued for consulting services (in shares) |
|
|
|
|
|
|
|
|
|
4,834,045
|
|
|
|
Non-cash consulting expense | $ |
|
|
|
|
|
|
|
|
|
$ 53,837
|
|
|
|
Common stock issued | $ |
|
|
|
|
|
|
|
|
|
$ 9,624
|
$ 2,579
|
|
|
Loss on conversion of convertible notes payable | $ |
|
|
|
|
|
|
|
|
|
|
$ 307
|
|
|
Common stock issued to settle note conversion (in shares) |
|
|
|
|
|
|
|
|
|
|
1,138,199
|
|
|
Awarded to employees as bonus for services provided |
|
|
|
|
|
|
|
|
|
200,000
|
|
|
|
Compensation expenses | $ |
|
|
|
|
|
|
|
|
|
$ 7,785
|
$ 730
|
|
|
Common shares issued |
|
|
|
|
|
|
|
|
|
|
30,020
|
|
|
Debt conversion, converted instrument, amount | $ |
|
|
|
|
|
|
|
|
|
|
$ 100
|
|
|
Debt conversion, original debt, amount | $ |
|
|
|
|
|
|
|
|
|
|
$ 100
|
|
|
Loss on settlement of accounts payable | $ |
|
|
|
|
|
|
|
|
|
$ (121)
|
|
|
|
Preferred stock, shares authorized |
|
|
|
|
|
|
|
|
|
50,000,000
|
50,000,000
|
|
|
Preferred stock, shares issued |
|
|
|
|
|
|
|
|
|
0
|
0
|
|
|
Preferred stock, par value | $ / shares |
|
|
|
|
|
|
|
|
|
$ 0.001
|
$ 0.001
|
|
|
Number of shares outstanding |
|
|
|
|
|
|
|
|
|
0
|
0
|
|
|
Warrant issued |
|
|
|
|
|
|
|
|
|
6,193,449
|
|
|
|
Warrant, exercise price per share | $ / shares |
|
|
|
|
|
|
|
|
|
$ 9.09
|
$ 1.09
|
|
|
Proceeds from exercise of warrant | $ |
|
$ 9,200
|
|
|
|
|
|
|
|
$ 16,699
|
|
|
|
Net impact to additional paid-in capital | $ |
|
|
|
|
|
|
|
|
|
$ 60,852
|
|
|
|
Number of outstanding warrants |
|
|
|
|
|
|
|
|
|
9,305,790
|
3,075,470
|
|
|
Change in fair value of the warrants | $ |
|
|
|
|
|
|
|
|
|
$ (1,692)
|
|
|
|
Number of units outstanding |
|
|
|
|
|
|
|
|
|
600,000
|
|
600,000
|
|
Price per unit | $ / shares |
|
|
|
|
|
|
|
|
|
$ 10.00
|
|
|
|
Aggregate exercise price | $ |
|
|
|
|
|
|
|
|
|
$ 6,000
|
|
|
|
Number of shares per right |
|
|
|
|
|
|
|
|
|
1
|
|
|
|
Fractional shares issued upon conversion of rights |
|
|
|
|
|
|
|
|
|
0
|
|
|
|
Unamortized compensation costs | $ |
|
|
|
|
|
|
|
|
|
$ 31,100
|
|
|
|
Common stock issued to settle accounts payable | $ |
|
|
|
|
|
|
|
|
|
|
$ 145
|
|
|
Loss on common stock issued to settle accounts payable | $ |
|
|
|
|
|
|
|
|
|
|
42
|
|
|
Substitute Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Deemed dividend - Earnout Shares | $ |
|
|
|
|
|
|
|
|
|
2,700
|
|
|
|
Net impact to additional paid-in capital | $ |
|
|
|
|
|
|
|
|
|
0
|
|
|
|
Additional deemed dividend recognized in the event of earnout shares milestone | $ |
|
|
|
|
|
|
|
|
|
24,400
|
|
|
|
Additional deemed dividend recognized in the event of earnout cash milestone | $ |
|
|
|
|
|
|
|
|
|
$ 3,100
|
|
|
|
Public Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant, exercise price per share | $ / shares |
|
|
|
|
|
|
|
|
|
$ 11.50
|
|
|
|
Warrants exercised |
|
|
|
|
|
|
|
|
|
1,144
|
|
|
|
Number of outstanding warrants |
|
|
|
|
|
|
|
|
|
3,450,000
|
|
|
|
Number of shares per warrant |
|
|
|
|
|
|
|
|
|
1
|
|
|
|
Warrants expiration term |
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
Redemption price per warrant (in dollars per share) | $ / shares |
|
|
|
|
|
|
|
|
|
$ 0.01
|
|
|
|
Minimum threshold written notice period for redemption of warrants |
|
|
|
|
|
|
|
|
|
30 days
|
|
|
|
Stock price trigger for redemption of warrants (in dollars per share) | $ / shares |
|
|
|
|
|
|
|
|
|
$ 21.00
|
|
|
|
Threshold trading days for redemption of warrants | D |
|
|
|
|
|
|
|
|
|
20
|
|
|
|
Redemption period | D |
|
|
|
|
|
|
|
|
|
30
|
|
|
|
Public Warrants | Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross proceeds from exercise of warrants | $ |
|
|
|
|
|
|
|
|
|
$ 100
|
|
|
|
Placement Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of outstanding warrants |
|
|
|
|
|
|
|
|
|
136,250
|
|
|
|
Change in fair value of the warrants | $ |
|
|
|
|
|
|
|
|
|
$ 1,700
|
0
|
|
|
Public Right |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of outstanding warrants |
|
|
|
|
|
|
|
|
|
6,900,000
|
|
|
|
Placement Rights |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of outstanding warrants |
|
|
|
|
|
|
|
|
|
272,500
|
|
|
|
GEM Warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingently issuable Earnout Shares Excluded from EPS computation |
|
|
|
|
|
|
|
|
|
1,044,453
|
|
|
|
Merger agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Merger and PIPE Financing shares - common stock |
|
|
|
|
|
|
|
|
|
3,729,730
|
|
|
|
Exchange Ratio |
|
|
3.16
|
|
|
|
|
|
|
|
|
|
|
Merger agreement | Stockholders of NeuroRx |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Exchange Ratio |
|
|
3.16
|
4.96
|
|
|
|
|
|
|
|
|
|
VaccineCo |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Merger and PIPE Financing shares - common stock |
4,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant issued |
|
|
|
|
|
139,645
|
279,291
|
4,000
|
|
|
|
|
|
Warrant, exercise price per share | $ / shares |
|
|
|
|
|
$ 15.25
|
$ 15.25
|
$ 15.25
|
|
|
|
|
|
Warrant expiry date |
|
|
|
|
|
Oct. 22, 2025
|
Jul. 14, 2025
|
Jul. 05, 2023
|
|
|
|
|
|
Fair value on the date of issuance | $ |
|
|
|
|
|
$ 2,700
|
$ 2,700
|
$ 100
|
|
|
|
|
|
Warrant, fair valued price per share | $ / shares |
|
|
|
|
|
$ 9.64
|
$ 9.63
|
$ 7.63
|
|
|
|
|
|
Common stock Warrants | Legacy NeuroRx Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant issued |
|
|
|
|
3,329,812
|
|
|
|
|
|
|
|
|
Warrant, exercise price per share | $ / shares |
|
|
|
|
$ 3.19
|
|
|
|
|
|
|
|
|
Warrant expiry date |
|
|
|
|
Mar. 27, 2024
|
|
|
|
|
|
|
|
|
Fair value on the date of issuance | $ |
|
|
|
|
$ 60,900
|
|
|
|
|
|
|
|
|
Warrants exercised |
|
1,833,596
|
|
|
1,496,216
|
|
|
|
|
|
|
|
|
Gross proceeds from exercise of warrants | $ |
|
$ 9,200
|
|
|
$ 7,500
|
|
|
|
|
|
|
|
|
Substitute Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant, exercise price per share | $ / shares |
|
|
|
|
|
|
|
|
|
$ 2.45
|
|
|
|
Warrants exercised |
|
|
|
|
|
|
|
|
|
4,909,066
|
|
|
|
Incremental compensation on modification | $ |
|
|
|
|
|
|
|
|
|
$ 2,300
|
|
|
|
Unamortized compensation costs | $ |
|
|
|
|
|
|
|
|
|
23,800
|
|
|
|
General and Administrative Expense [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash consulting expense | $ |
|
|
|
|
|
|
|
|
|
53,800
|
|
|
|
Compensation expenses | $ |
|
|
|
|
|
|
|
|
|
$ 6,500
|
332
|
|
|
Loss on settlement of accounts payable | $ |
|
|
|
|
|
|
|
|
|
|
$ 100
|
|
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Merger and PIPE Financing shares - common stock |
|
|
|
|
|
|
|
|
|
3,642,727
|
556,043
|
|
|
Issuance of common stock for exercise of warrants and Unit Purchase Options (in shares) |
|
|
|
|
|
|
|
|
|
3,830,586
|
|
|
|
Proceeds from issuance of common stock | $ |
|
|
|
|
|
|
|
|
|
$ 37,000
|
$ 2,600
|
|
|
Common Stock | General and Administrative Expense [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Compensation expenses | $ |
|
|
|
|
|
|
|
|
|
$ 4,800
|
|
|
|
Legacy NeuroRx Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, par value | $ / shares |
|
|
|
|
|
|
|
|
|
$ 0.001
|
$ 0.001
|
|
|
Legacy NeuroRx Preferred Stock | Convertible Series A Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, shares authorized |
|
|
|
|
|
|
|
|
|
1,000,000
|
1,000,000
|
|
|
Preferred stock, shares issued |
|
|
|
|
|
|
|
|
|
1,000,000
|
1,000,000
|
|
|
Preferred stock, conversion basis |
|
|
|
|
|
|
|
|
|
one share of common stock for each preferred share
|
|
|
|
Convertible preferred stock, liquidation preference per share | $ / shares |
|
|
|
|
|
|
|
|
|
$ 1.00
|
$ 1.00
|
|
|
Number of shares outstanding |
|
|
2,367,543
|
|
|
|
|
|
|
|
|
|
|
Shares issued upon conversion |
|
|
7,480,836
|
|
|
|
|
|
|
|
|
|
|
Legacy NeuroRx Preferred Stock | Convertible Series B-1 Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, shares authorized |
|
|
|
|
|
|
|
|
|
1,050,695
|
1,050,695
|
|
|
Preferred stock, shares issued |
|
|
|
|
|
|
|
|
|
1,050,695
|
1,050,695
|
|
|
Convertible preferred stock, liquidation preference per share | $ / shares |
|
|
|
|
|
|
|
|
|
$ 7.58
|
$ 7.58
|
|
|
Legacy NeuroRx Preferred Stock | Convertible Series B-1A Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, shares authorized |
|
|
|
|
|
|
|
|
|
316,848
|
316,848
|
|
|
Preferred stock, shares issued |
|
|
|
|
|
|
|
|
|
316,848
|
316,848
|
|
|
Convertible preferred stock, liquidation preference per share | $ / shares |
|
|
|
|
|
|
|
|
|
$ 6.82
|
$ 6.82
|
|
|
Legacy NeuroRx Preferred Stock | Convertible Series B-2 Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, shares authorized |
|
|
|
|
|
|
|
|
|
|
100,000
|
|
|
Preferred stock, shares issued |
|
|
|
|
|
|
|
|
|
|
|
|
4,167
|
Preferred stock, par value | $ / shares |
|
|
|
|
|
|
|
|
|
|
$ 0.001
|
|
|
Preferred stock, conversion basis |
|
|
|
|
|
|
|
|
|
|
one share of common stock for each share of B-2 Preferred Stock
|
|
|
Convertible preferred stock, liquidation preference per share | $ / shares |
|
|
|
|
|
|
|
|
|
|
$ 12.00
|
|
|
Number of shares outstanding |
|
|
4,167
|
|
|
|
|
|
|
|
|
|
|
Shares issued upon conversion |
|
|
13,168
|
|
|
|
|
|
|
|
|
|
|